A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer


Condition: Bladder Cancer, Bladder Tumors, Neoplasms, Bladder

Intervention:

  • Biological: Nivolumab
  • Biological: BCG
  • Drug: BMS-986205

Purpose: A study to evaluate Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03519256

Sponsor: Bristol-Myers Squibb

Primary Outcome Measures:

  • Measure: Proportion of carcinoma in situ (CIS) participants with complete response (CR), per Pathology Review Committee (PRC)
  • Time Frame: Up to 5 years
  • Safety Issue:
  • Measure: Duration of complete response (DOCR), per PRC, in CIS participants with CR
  • Time Frame: Up to 5 years
  • Safety Issue:
  • Measure: Event Free Survival (EFS), per PRC, for all non-CIS participants
  • Time Frame: Up to 5 years
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Progression-free Survival (PFS)
  • Time Frame: Up to 5 years
  • Safety Issue:
  • Measure: Incidence of Adverse Events (AEs)
  • Time Frame: Up to 15 months
  • Safety Issue:
  • Measure: Incidence of Serious Adverse Events (SAEs)
  • Time Frame: Up to 15 months
  • Safety Issue:
  • Measure: Incidence of AEs leading to discontinuation
  • Time Frame: Up to 15 months
  • Safety Issue:
  • Measure: Incidence of deaths
  • Time Frame: Up to 5 years
  • Safety Issue:
  • Measure: Incidence of laboratory abnormalities
  • Time Frame: Up to 15 months
  • Safety Issue:

Estimated Enrollment: 436

Study Start Date: May 25, 2018

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • Pathologically demonstrated BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) defined as CIS with or without papillary component, any T1, or Ta high-grade lesions
  • Predominant histologic component (> 50%) must be urothelial (transitional cell) carcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Exclusion Criteria:
  • Sign of locally advanced disease or metastatic bladder cancer
  • Urothelial cancer (UC) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment
  • Prior immuno-oncology therapy Other protocol defined inclusion/

Exclusion Criteria:

  • Sign of locally advanced disease or metastatic bladder cancer
  • Urothelial cancer (UC) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment
  • Prior immuno-oncology therapy Other protocol defined inclusion/exclusion criteria could apply

Contact:

  • Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
  • please email

Locations:

  • Local Institution
  • Phoenix Arizona 85054 United States
  • USC Norris Comprehensive Cancer Center
  • Los Angeles California 90033 United States
  • Local Institution
  • Riverside California 92505 United States
  • Local Institution
  • San Francisco California 94158 United States
  • Moffitt Cancer Center
  • Tampa Florida 33612 United States
  • Emory University
  • Atlanta Georgia 30322 United States
  • The University Of Chicago
  • Chicago Illinois 60637 United States
  • Local Institution
  • Westwood Kansas 66205 United States
  • Wichita Urology Group
  • Wichita Kansas 67226 United States
  • Local Institution
  • Shreveport Louisiana 71106 United States
  • Johns Hopkins University
  • Baltimore Maryland 21287 United States
  • University Of Michigan
  • Ann Arbor Michigan 48109 United States
  • University Of Minnesota
  • Minneapolis Minnesota 55455 United States
  • Adult & Pediatric Urology
  • Omaha Nebraska 68114 United States
  • Deleware Valley Urology, LLC
  • Voorhees New Jersey 08043 United States
  • Laura & Isaac Perlmutter Cancer Center
  • New York New York 10016 United States
  • Local Institution
  • New York New York 10032 United States
  • Local Institution
  • New York New York 10065 United States
  • James Cancer Hospital
  • Columbus Ohio 43212 United States
  • Local Institution
  • Springfield Oregon 97477 United States
  • MidLantic Urology
  • Bala-Cynwyd Pennsylvania 19004 United States
  • Local Institution
  • Hershey Pennsylvania 17033 United States
  • Medical University Of South Carolina
  • Charleston South Carolina 29425 United States
  • Carolina Urologic Research Center
  • Myrtle Beach South Carolina 29572 United States
  • Erlanger Health System
  • Chattanooga Tennessee 37403 United States
  • Local Institution
  • Nashville Tennessee 37232 United States
  • Urology Clinics Of North Texas, Pa
  • Dallas Texas 75231 United States
  • Local Institution
  • Houston Texas 77030 United States
  • Local Institution
  • Houston Texas 77030 United States
  • Texas Tech University Health Sciences Center
  • Lubbock Texas 79415 United States
  • Urology San Antonio Research, Pa
  • San Antonio Texas 78229 United States
  • Local Institution
  • Virginia Beach Virginia 23462 United States
  • Local Institution
  • Seattle Washington 98195 United States
  • Instituto Medico Especializado Alexander Fleming
  • Capital Federal Buenos Aires 1426 Argentina
  • Local Institution
  • Ciudad Autonoma Buenos Aires Buenos Aires 1118 Argentina
  • Hospital Britanico De Buenos Aires
  • Ciudad Autonoma de Buenos Aires Buenos Aires 1280 Argentina
  • Clinica Viedma S.A.
  • Viedma RIO Negro 8500 Argentina
  • Instituto Oncologico De Cordoba
  • Cordoba 5000 Argentina
  • Local Institution
  • Fortaleza Ceara 60130-241 Brazil
  • Local Institution
  • Porto Alegre RIO Grande DO SUL 91350-200 Brazil
  • Local Institution
  • Campinas SAN Paulo 13075-460 Brazil
  • Local Institution
  • Itacorubi, Florianopolis Santa Catarina 88034 Brazil
  • Local Institution
  • Jau SAO Paulo 17210-080 Brazil
  • Local Institution
  • Sao Paulo 01246-000 Brazil
  • Local Institution
  • Edmonton Alberta T6R0N1 Canada
  • Local Institution
  • St. John's Newfoundland and Labrador A1B 3V6 Canada
  • Local Institution
  • Toronto Ontario M4N 3M5 Canada
  • Local Institution
  • Toronto Ontario M5G 1X6 Canada
  • Local Institution
  • Sherbrooke Quebec J1H 5N4 Canada
  • Local Institution
  • Quebec G1R 2J6 Canada
  • Fundacion Arturo Lopez Perez
  • Santiago Metropolitana Chile
  • Local Institution
  • Beijing Beijing 100034 China
  • Local Institution
  • Beijing Beijing 100142 China
  • Local Institution
  • Beijing Beijing 100191 China
  • Local Institution
  • Beijing Beijng 100021 China
  • Local Institution
  • Chongqing Chongqing 400030 China
  • Local Institution
  • Fuzhou Fujian 350001 China
  • Local Institution
  • Guangzhou Guangdong 510080 China
  • Local Institution
  • Nanjing Jiangsu 210008 China
  • Local Institution
  • Nanchang Jiangxi China
  • Local Institution
  • Jinan Shadong 250012 China
  • Local Institution
  • Yantai Shandong 264000 China
  • Local Institution
  • Shanghai Shanghai 200025 China
  • Local Institution
  • Shanghai Shanghai 200032 China
  • Local Institution
  • Shanghai Shanghai 200040 China
  • Local Institution
  • Shanghai Shanghai 200433 China
  • Local Institution
  • Chengdu Sichuan 610041 China
  • Local Institution
  • Tianjin Tianjin 300211 China
  • Local Institution
  • Hang'zhou Zhejiang 310000 China
  • Local Institution
  • Shanghai 200032 China
  • Chu Angers
  • Angers 49100 France
  • Local Institution
  • Bordeaux 33000 France
  • Local Institution
  • LILLE Cedex 59037 France
  • Local Institution
  • Strasbourg Cedex 67091 France
  • Local Institution
  • Suresnes 92151 France
  • Local Institution
  • Hong Kong Hong Kong
  • IRCCS Istituto Nazionale Tumori Milano
  • Milano 20133 Italy
  • Local Institution
  • Modena 41100 Italy
  • Instituto Nazionale Tumori Fondazione G. Pascale
  • Napoli 80131 Italy
  • Azienda Ospedaliera Universitaria Pisana
  • Pisa 56126 Italy
  • Centro De Estudios Y Prevencion Del Cancer A. C.
  • Tuxtla Gutierrez Chiapas 290838 Mexico
  • Cryptex Investigacion Clinica Sa de Cv
  • Ciudad de Mexico Distrito Federal 06100 Mexico
  • Local Institution
  • Df Distrito Federal 06720 Mexico
  • Local Institution
  • Amsterdam 1066 CX Netherlands
  • Local Institution
  • Nijmegen 6525 GA Netherlands
  • Local Institution
  • Utrecht 3584CX Netherlands
  • Local Institution
  • Omsk 644013 Russian Federation
  • Local Institution
  • Saint-Petersburg 194044 Russian Federation
  • Local Institution
  • Barcelona 08025 Spain
  • Local Institution
  • Madrid 28041 Spain
  • Local Institution
  • Malaga 29010 Spain
  • Local Institution
  • Santander 39008 Spain
  • Local Institution
  • Valencia 46010 Spain
  • Local Institution
  • Istanbul 34000 Turkey
  • Local Institution
  • Istanbul 34214 Turkey
  • Local Institution
  • Istanbul 34300 Turkey
  • Local Institution
  • Plymouth Devon PL6 8DH United Kingdom
  • Local Institution
  • Chelmsford Essex CM1 7ET United Kingdom
  • Local Institution
  • London Greater London N18 1QX United Kingdom
  • Local Institution
  • Southampton Hampshire SO16 6YD United Kingdom
  • Local Institution
  • Lancaster LA1 4RP United Kingdom
  • Local Institution
  • London NW1 2BU United Kingdom

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe